NCT02089087View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 7, 2013

Primary Completion Date

February 3, 2017

Study Completion Date

February 3, 2017

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CFZ533

Single dose at varying dosage levels depending on treatment assignment

DRUG

Placebo

Trial Locations (6)

110

Novartis Investigative Site, Taipei

16635

Novartis Investigative Site, Duncansville

33136

Novartis Investigative Site, Miami

33143

Novartis Investigative Site, South Miami

68502

Novartis Investigative Site, Lincoln

36207-5710

Novartis Investigative Site, Anniston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY